• Consensus Rating: Buy
  • Consensus Price Target: $4.58
  • Forecasted Upside: 316.67%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.10
▲ +0.05 (4.76%)

This chart shows the closing price for ASRT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Assertio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ASRT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ASRT

Analyst Price Target is $4.58
▲ +316.67% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Assertio in the last 3 months. The average price target is $4.58, with a high forecast of $7.00 and a low forecast of $2.75. The average price target represents a 316.67% upside from the last price of $1.10.

This chart shows the closing price for ASRT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Assertio. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/22/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/19/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/28/2024Alliance Global PartnersInitiated CoverageBuy$2.75Low
11/3/2023BWS FinancialLower TargetBuy ➝ Buy$6.00 ➝ $4.00Low
8/4/2023BWS FinancialLower TargetBuy ➝ Buy$10.00 ➝ $6.00Low
8/4/2023Lake Street CapitalLower Target$9.00 ➝ $7.00Low
5/10/2023BWS FinancialBoost Target$8.00 ➝ $10.00Low
5/10/2023Lake Street CapitalBoost Target$8.00 ➝ $9.00Low
3/3/2023BWS FinancialBoost TargetBuy$6.00 ➝ $8.00Low
11/7/2022Lake Street CapitalInitiated CoverageBuy$7.00Low
8/24/2022Roth CapitalReiterated RatingBuyLow
5/18/2022BWS FinancialInitiated CoverageBuyLow
4/13/2021GabelliUpgradeHold ➝ BuyLow
4/6/2021GabelliReiterated RatingHold ➝ HoldHigh
12/17/2020GabelliDowngradeBuy ➝ HoldHigh
9/18/2020G.ResearchReiterated RatingBuyMedium
9/18/2020GabelliInitiated CoverageBuyHigh
8/20/2020Roth CapitalReiterated RatingBuyHigh
6/3/2020Brookline Capital ManagementInitiated CoverageBuy$3.50Low
(Data available from 6/19/2019 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/21/2023
  • 5 very positive mentions
  • 7 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
1/20/2024
  • 3 very positive mentions
  • 17 positive mentions
  • 8 negative mentions
  • 3 very negative mentions
2/19/2024
  • 5 very positive mentions
  • 32 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
3/20/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2024
  • 3 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/19/2024
  • 7 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/18/2024

Current Sentiment

  • 7 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Assertio logo
Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
Read More

Today's Range

Now: $1.10
Low: $1.02
High: $1.20

50 Day Range

MA: $0.97
Low: $0.75
High: $1.22

52 Week Range

Now: $1.10
Low: $0.73
High: $6.41

Volume

1,185,934 shs

Average Volume

941,195 shs

Market Capitalization

$104.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Assertio?

The following Wall Street research analysts have issued reports on Assertio in the last year: Alliance Global Partners, BWS Financial, Lake Street Capital, StockNews.com, and TheStreet.
View the latest analyst ratings for ASRT.

What is the current price target for Assertio?

3 Wall Street analysts have set twelve-month price targets for Assertio in the last year. Their average twelve-month price target is $4.58, suggesting a possible upside of 316.7%. Lake Street Capital has the highest price target set, predicting ASRT will reach $7.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $2.75 for Assertio in the next year.
View the latest price targets for ASRT.

What is the current consensus analyst rating for Assertio?

Assertio currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ASRT will outperform the market and that investors should add to their positions of Assertio.
View the latest ratings for ASRT.

What other companies compete with Assertio?

How do I contact Assertio's investor relations team?

Assertio's physical mailing address is 100 South Saunders Road Suite 300, Lake Forest IL, 60045. The company's listed phone number is (224) 419-7106 and its investor relations email address is [email protected]. The official website for Assertio is www.assertiotx.com. Learn More about contacing Assertio investor relations.